CSF and Brain Structural Imaging Markers of the Alzheimer's Pathological Cascade

被引:32
|
作者
Yang, Xianfeng [1 ]
Tan, Ming Zhen [1 ]
Qiu, Anqi [1 ,2 ,3 ]
机构
[1] Natl Univ Singapore, Dept Bioengn, Singapore 117548, Singapore
[2] Natl Univ Singapore, Clin Imaging Res Ctr, Singapore 117548, Singapore
[3] Singapore Inst Clin Sci, Agcy Sci Technol & Res, Singapore, Singapore
来源
PLOS ONE | 2012年 / 7卷 / 12期
基金
英国医学研究理事会;
关键词
MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; HIPPOCAMPAL ATROPHY; DISEASE; MRI; RECOMMENDATIONS; BIOMARKERS; DEMENTIA;
D O I
10.1371/journal.pone.0047406
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cerebral spinal fluid (CSF) and structural imaging markers are suggested as biomarkers amended to existing diagnostic criteria of mild cognitive impairment (MCI) and Alzheimer's disease (AD). But there is no clear instruction on which markers should be used at which stage of dementia. This study aimed to first investigate associations of the CSF markers as well as volumes and shapes of the hippocampus and lateral ventricles with MCI and AD at the baseline and secondly apply these baseline markers to predict MCI conversion in a two-year time using the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Our results suggested that the CSF markers, including A beta 42, t-tau, and p-tau, distinguished MCI or AD from NC, while the A beta 42 CSF marker contributed to the differentiation between MCI and AD. The hippocampal shapes performed better than the hippocampal volumes in classifying NC and MCI, NC and AD, as well as MCI and AD. Interestingly, the ventricular volumes were better than the ventricular shapes to distinguish MCI or AD from NC, while the ventricular shapes showed better accuracy than the ventricular volumes in classifying MCI and AD. As the CSF markers and the structural markers are complementary, the combination of them showed great improvements in the classification accuracies of MCI and AD. Moreover, the combination of these markers showed high sensitivity but low specificity for predicting conversion from MCI to AD in two years. Hence, it is feasible to employ a cross-sectional sample to investigate dynamic associations of the CSF and imaging markers with MCI and AD and to predict future MCI conversion. In particular, the volumetric information may be good for the early stage of AD, while morphological shapes should be considered as markers in the prediction of MCI conversion to AD together with the CSF markers.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Statistical Model of Dynamic Markers of the Alzheimer's Pathological Cascade
    Balsis, Steve
    Geraci, Lisa
    Benge, Jared
    Lowe, Deborah A.
    Choudhury, Tabina K.
    Tirso, Robert
    Doody, Rachelle S.
    JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES, 2018, 73 (06): : 964 - 973
  • [2] Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease
    Contador, Jose
    Perez-Millan, Agnes
    Tort-Merino, Adria
    Balasa, Mircea
    Falgas, Neus
    Olives, Jaume
    Castellvi, Magdalena
    Borrego-Ecija, Sergi
    Bosch, Beatriz
    Fernandez-Villullas, Guadalupe
    Ramos-Campoy, Oscar
    Antonell, Anna
    Bargallo, Nuria
    Sanchez-Valle, Raquel
    Sala-Llonch, Roser
    Llado, Albert
    NEUROIMAGE-CLINICAL, 2021, 32
  • [3] An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum
    Van Hulle, Carol
    Jonaitis, Erin M.
    Betthauser, Tobey J.
    Batrla, Richard
    Wild, Norbert
    Kollmorgen, Gwendlyn
    Andreasson, Ulf
    Okonkwo, Ozioma
    Bendlin, Barbara B.
    Asthana, Sanjay
    Carlsson, Cynthia M.
    Johnson, Sterling C.
    Zetterberg, Henrik
    Blennow, Kaj
    ALZHEIMERS & DEMENTIA, 2021, 17 (03) : 431 - 445
  • [4] A Focus on Structural Brain Imaging in the Alzheimer's Disease Neuroimaging Initiative
    Braskie, Meredith N.
    Thompson, Paul M.
    BIOLOGICAL PSYCHIATRY, 2014, 75 (07) : 527 - 533
  • [5] Alzheimer's disease CSF biomarkers: clinical indications and rational use
    Niemantsverdriet, Ellis
    Valckx, Sara
    Bjerke, Maria
    Engelborghs, Sebastiaan
    ACTA NEUROLOGICA BELGICA, 2017, 117 (03) : 591 - 602
  • [6] CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade
    Stricker, Nikki H.
    Dodge, Hiroko H.
    Dowling, N. Maritza
    Han, S. Duke
    Erosheva, Elena A.
    Jagust, William J.
    BRAIN IMAGING AND BEHAVIOR, 2012, 6 (04) : 599 - 609
  • [7] Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls
    Wittens, Mandy Melissa Jane
    Allemeersch, Gert-Jan
    Sima, Diana Maria
    Naeyaert, Maarten
    Vanderhasselt, Tim
    Vanbinst, Anne-Marie
    Buls, Nico
    De Brucker, Yannick
    Raeymaekers, Hubert
    Fransen, Erik
    Smeets, Dirk
    van Hecke, Wim
    Nagels, Guy
    Bjerke, Maria
    de Mey, Johan
    Engelborghs, Sebastiaan
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [8] Imaging markers for Alzheimer disease Which vs how
    Frisoni, Giovanni B.
    Bocchetta, Martina
    Chetelat, Gael
    Rabinovici, Gil D.
    de Leon, Mony J.
    Kaye, Jeffrey
    Reiman, Eric M.
    Scheltens, Philip
    Barkhof, Frederik
    Black, Sandra E.
    Brooks, David J.
    Carrillo, Maria C.
    Fox, Nick C.
    Herholz, Karl
    Nordberg, Agneta
    Jack, Clifford R., Jr.
    Jagust, William J.
    Johnson, Keith A.
    Rowe, Christopher C.
    Sperling, Reisa A.
    Thies, William
    Wahlund, Lars-Olof
    Weiner, Michael W.
    Pasqualetti, Patrizio
    DeCarli, Charles
    NEUROLOGY, 2013, 81 (05) : 487 - 500
  • [9] Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease
    Ota, Kenichi
    Oishi, Naoya
    Ito, Kengo
    Fukuyama, Hidenao
    JOURNAL OF NEUROSCIENCE METHODS, 2015, 256 : 168 - 183
  • [10] Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease
    Alexopoulos, Panagiotis
    Roesler, Jennifer
    Thierjung, Nathalie
    Werle, Lukas
    Buck, Dorothea
    Yakushev, Igor
    Gleixner, Lena
    Kagerbauer, Simone
    Ortner, Marion
    Grimmer, Timo
    Kuebler, Hubert
    Martin, Jan
    Laskaris, Nikolaos
    Kurz, Alexander
    Perneczky, Robert
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2016, 266 (07) : 587 - 597